Overview

Montelukast Post-Marketing Comparative Study With Ketotifen (0476-379)

Status:
Completed
Trial end date:
2004-06-16
Target enrollment:
Participant gender:
Summary
The clinical study evaluates the safety of montelukast and compares montelukast to ketotifen, used as a control drug, in terms of improvement in morning peak expiratory flow (am pef) over first 2 weeks in patients with pediatric bronchial asthma aged 6 to < 15. The effect of body weight on the efficacy and safety of montelukast will also be evaluated in this study.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ketotifen
Montelukast